Identification of FDA-approved drugs that induce heart regeneration in mammals

Mahmoud Salama Ahmed,Ngoc Uyen Nhi Nguyen,Yuji Nakada,Ching-Cheng Hsu,Ayman Farag,Nicholas T Lam,Ping Wang,Suwannee Thet,Ivan Menendez-Montes,Waleed M Elhelaly,Xi Lou,Ilaria Secco,Mateusz Tomczyk,Lorena Zentilin,Jimin Pei,Miao Cui,Matthieu Dos Santos,Xiaoye Liu,Yan Liu,David Zaha,Gregory Walcott,Diana R Tomchick,Chao Xing,Cheng Cheng Zhang,Nick V Grishin,Mauro Giacca,Jianyi Zhang,Hesham A Sadek

DOI: https://doi.org/10.1038/s44161-024-00450-y

Abstract:Targeting Meis1 and Hoxb13 transcriptional activity could be a viable therapeutic strategy for heart regeneration. In this study, we performd an in silico screening to identify FDA-approved drugs that can inhibit Meis1 and Hoxb13 transcriptional activity based on the resolved crystal structure of Meis1 and Hoxb13 bound to DNA. Paromomycin (Paro) and neomycin (Neo) induced proliferation of neonatal rat ventricular myocytes in vitro and displayed dose-dependent inhibition of Meis1 and Hoxb13 transcriptional activity by luciferase assay and disruption of DNA binding by electromobility shift assay. X-ray crystal structure revealed that both Paro and Neo bind to Meis1 near the Hoxb13-interacting domain. Administration of Paro-Neo combination in adult mice and in pigs after cardiac ischemia/reperfusion injury induced cardiomyocyte proliferation, improved left ventricular systolic function and decreased scar formation. Collectively, we identified FDA-approved drugs with therapeutic potential for induction of heart regeneration in mammals.